perinatologyРоссийский вестник перинатологии и педиатрииRossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)1027-40652500-2228Ltd. “The National Academy of Pediatric Science and Innovation”perinatology-92Research ArticleВОПРОСЫ ФАРМАКОТЕРАПИИВОПРОСЫ ФАРМАКОТЕРАПИИАнтибактериальная активность тобрамицина в отношении штаммов Pseudomonas aeruginosa, выделенных у больных муковисцидозомAntimicrobial activity of tobramycin against Pseudomonas aeruginosa strains isolated from patients with cystic fibrosisПереновскаП.PerenovskaP.СтояноваГ.StoyanovaG.СтратеваТ.StratevaT.Кафедра медицинской микробиологии, Медицинский университет, София, Болгария; Клиника педиатрии, УМБАЛ «Александровска», Медицинский университет, София, БолгарияBulgaria2015100320166018992Copyright © Ltd. “The National Academy of Pediatric Science and Innovation”, 20162016Ltd. “The National Academy of Pediatric Science and Innovation”Ltd. “The National Academy of Pediatric Science and Innovation”https://www.ped-perinatology.ru/jour/about/submissions#copyrightNoticehttps://www.ped-perinatology.ru/jour/article/view/92

Инфекции нижних дыхательных путей у пациентов с муковисцидозом характеризуются упорно рецидивирующим и тяжелым течением. Для лечения заболеваний, вызванных Peudomonas aeruginosa, в последнее время у детей старше 6 лет успешно применяется тобрамицин в ингаляциях. В настоящем исследовании методом E-test (LIOFILCHEM, Италия) определена антибактериальная активность тобрамицина в отношении 40 штаммов P. aeruginosa, выделенных у 25 больных муковисцидозом за период 2005-2009 гг. При этом МПК50 и МПК^ составили соответственно 0,75 и 3,0 мг/мл. Зависимости от возраста пациентов (и длительности колонизации с P. aeruginosa) не установлено. Тобрамицин in vitro показал высокую активность в отношении штаммов P. aeruginosa, выделенных у больных муковисцидозом. Она зависела от морфологии штамма и предшествующего лечения ингаляционным тобрамицином. При назначении ингаляционного лечения в случаях высева среднечувствительных или резистентных штаммов P. Aeruginosa (согласно критериям CLSI) необходимо интерпретировать оценку их чувствительности исходя из критериев MENSURA Group.

In patients with cystic flbrosis, lower respiratory tract infections are characterized by a steadily recurrent and severe course. Recently, inhaled tobramycin has been successfully used to treat Pseudomonas aeruginosa-iniucei diseases in children aged over 6 years. In this trial, the E-test (Liofilchem, Italy) was employed to determine the antimicrobial activity of tobramycin against 40 P. aeruginosa strains isolated from 25 patients with cystic fibrosis in the period 2005—2009. At the same time MIC50 and MIC90 were 0,75 and 3,0 mg/ml, respectively. No relationship to patient age (and duration of P. aeruginosa colonization) was established. Tobramycin showed high activity in vitro against P. aeruginosa strains isolated from the patients with cystic flbrosis. The activity was related to the morphology of a strain and previous treatment with inhaled tobramycin. When initiating its inhalation treatment in cases of inoculation of moderately susceptible or resistant P. aeruginosa strains (according to the CLSI criteria), it is necessary to interpret their susceptibility test results by following the MENSURA Group criteria.

детимуковисцидозP. aeruginosaантибактериальная активностьтобрамицин.childrencystic fibrosisP. aeruginosaantimicrobial activitytobramycin.ReferencesСтратева Т. Pseudomonas aeruginosa — феномен на бак-териална резистентност. Съвременна медицина 2007; 2: 25-40.Стратева Т. Pseudomonas aeruginosa — феномен на бак-териална резистентност. Съвременна медицина 2007; 2: 25-40.Ratjen F., Boring G. Cystic fibrosis (seminar). Lancet 2003; 361:681-689.Ratjen F., Boring G. Cystic fibrosis (seminar). Lancet 2003; 361:681-689.Henry R.L., Mellis СМ., Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediat Pulmonol 1992; 12: 158-161.Henry R.L., Mellis СМ., Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediat Pulmonol 1992; 12: 158-161.Ramsey B.W., Pepe M.S., Quan J.M. et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340: 23-30.Ramsey B.W., Pepe M.S., Quan J.M. et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340: 23-30.Canton R., Cobos N., de Gracia J. et al. Antimicrobial therapy for pulmonary pathogenic colonization and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect 2005; 11:9:690-703.Canton R., Cobos N., de Gracia J. et al. Antimicrobial therapy for pulmonary pathogenic colonization and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect 2005; 11:9:690-703.CLSI (2007). Performance standards for antimicrobial susceptibility testing; 17th informational supplement. CLSI M100-S17. Clinical and Laboratory Standards Institute, Wayne P. A. www.microbiolab-bg.com>CLSI.pdfCLSI (2007). Performance standards for antimicrobial susceptibility testing; 17th informational supplement. CLSI M100-S17. Clinical and Laboratory Standards Institute, Wayne P. A. www.microbiolab-bg.com>CLSI.pdfMorosini M.I., Garcia-Castillo M., Loz,a E. et al. Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips. J Clin Microbiol 2005; 43: 9: 4480-4485.Morosini M.I., Garcia-Castillo M., Loz,a E. et al. Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips. J Clin Microbiol 2005; 43: 9: 4480-4485.Cystic Fibrosis Foundation. 1994. Microbiology and infectious disease in cystic fibrosis. Consensus Conference: Concepts in Care. Vol. 5, section 1. Bethesda, MD: Cystic Fibrosis Foundation, www.cysticfibrosis.org.uk/Cystic Fibrosis Foundation. 1994. Microbiology and infectious disease in cystic fibrosis. Consensus Conference: Concepts in Care. Vol. 5, section 1. Bethesda, MD: Cystic Fibrosis Foundation, www.cysticfibrosis.org.uk/Geller D.E., Pitlick W.H., Nardella PA. et al. Pharmacokine-tics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122: 219-226.Geller D.E., Pitlick W.H., Nardella PA. et al. Pharmacokine-tics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122: 219-226.Pitt T.L., Sparrow M., Stefanidou M. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents.Pitt T.L., Sparrow M., Stefanidou M. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents.Thorax 2003; 58: 9: 794-796.Thorax 2003; 58: 9: 794-796.Govan J.R., Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepa-cia. Microbiol Rev 1996; 60: 3: 539-574.Govan J.R., Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepa-cia. Microbiol Rev 1996; 60: 3: 539-574.Mah T.F., Pitts В., Pellock B. et al. A genetic basis for Pseudomonas aeruginosa biofilm antimicrobial resistance. Nature 2003; 426: 6964: 306-310.Mah T.F., Pitts В., Pellock B. et al. A genetic basis for Pseudomonas aeruginosa biofilm antimicrobial resistance. Nature 2003; 426: 6964: 306-310.Zhang L., Mah T.F. Involvement of a novel efflux system inbiofilm-specific resistance to antibiotics. J Bacteriol 2008; 190: 13: 4447-4452.Zhang L., Mah T.F. Involvement of a novel efflux system inbiofilm-specific resistance to antibiotics. J Bacteriol 2008; 190: 13: 4447-4452.Ciofu O., Fussing V., Bagge N. et al. Characterization of pared mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, |3-lactamase activity and ribotyping. J Antimicrob Chemother 2001; 48: 3:391-396.Ciofu O., Fussing V., Bagge N. et al. Characterization of pared mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, |3-lactamase activity and ribotyping. J Antimicrob Chemother 2001; 48: 3:391-396.Shawar R.M., MacLeod D.L., Garber R.L. et al. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999; 43: 12: 2877-2880.Shawar R.M., MacLeod D.L., Garber R.L. et al. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999; 43: 12: 2877-2880.Schulin T. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J Antimicrob Chemother 2002; 49: 2: 403-406.Schulin T. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J Antimicrob Chemother 2002; 49: 2: 403-406.Burns J.L., Van Dalfsen J.M., Shawar R.M. et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999; 179: 5:1190-1196.Burns J.L., Van Dalfsen J.M., Shawar R.M. et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999; 179: 5:1190-1196.Hoffman L.R., D'Argenio D.A., MacCoss M.J. et al. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 2005; 436: 7054: 1171-1175.Hoffman L.R., D'Argenio D.A., MacCoss M.J. et al. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 2005; 436: 7054: 1171-1175.

The authors declare that there are no conflicts of interest present.